Back to top
more

BioNTech (BNTX)

(Delayed Data from NSDQ)

$111.77 USD

111.77
1,320,094

-2.70 (-2.36%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $111.72 -0.05 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Pfizer (PFE), BioNTech Post Data on COVID Jab for Kids Under 5

by Zacks Equity Research

Pfizer (PFE) and BioNTech (BNTX) report updated data, showing that their three-dose COVID-19 vaccine is 73.2% effective in children under five years.

Moderna (MRNA) Seeks FDA Nod for Omicron-Based COVID Jab

by Zacks Equity Research

Moderna's (MRNA) bivalent COVID-19 booster vaccine, mRNA-1273.222, is designed to target the Omicron BA.4 and BA.5 subvariants. The vaccine has been developed specifically for the U.S. market.

Moderna (MRNA) to Supply Omicron-based COVID Jab in Canada

by Zacks Equity Research

Moderna's (MRNA) Omicron-specific bivalent vaccine booster is yet to be approved by Canadian health authorities. The government seeks to purchase 12 million doses of the same in 2022.

Pfizer (PFE), BioNTech Seek FDA Nod for Omicron Variant Booster

by Zacks Equity Research

Pfizer (PFE) and BioNTech's (BNTX) Omicron BA.4/BA.5-adapted bivalent vaccine contains mRNA encoding the spike protein present in the original vaccine as well as mRNA encoding the spike protein of the Omicron BA.4/BA.5 variant.

Novavax (NVAX) COVID-19 Vaccine Gets FDA Nod for Adolescents

by Zacks Equity Research

Post the label expansion by the FDA, Novavax's (NVAX) COVID-19 vaccine is the first protein-based COVID vaccine authorized for use in individuals aged 12 years and older in the United States.

Novavax (NVAX) Seeks FDA Authorization for COVID-19 Booster Dose

by Zacks Equity Research

Novavax (NVAX) seeks label expansion from the FDA for its COVID-19 vaccine as a booster dose in adults. The vaccine is authorized as a primary two-dose regimen in adults.

Novavax's (NVAX) COVID Vaccine Aids Growth, Overdependence Ails

by Zacks Equity Research

Currently, Novavax (NVAX) has only one marketed product in its portfolio, its protein-based COVID-19 vaccine. However, it is lagging in competition behind mRNA-based vaccines.

Novavax (NVAX) Q2 Earnings Miss, Cuts '22 Sales Guidance by Half

by Zacks Equity Research

Novavax (NVAX) reports dismal results in second-quarter 2022. The stock dives in after-market trading after management slashes revenue guidance for 2022 by half.

Company News for Aug 9, 2022

by Zacks Equity Research

Companies in The News Are: GOLD,HE,BNTX,VTRS

BioNTech's (BNTX) Earnings & Revenues Miss Estimates in Q2

by Zacks Equity Research

BioNTech (BNTX) misses estimates for both earnings and revenues in the second quarter of 2022.

Amicus (FOLD) Q2 Earnings Beat, Galafold Sales Miss Estimates

by Zacks Equity Research

Amicus Therapeutics (FOLD) posts a narrower-than-expected loss for the second quarter. FOLD's sole marketed drug Galafold's solid sales drive the top line.

Amgen (AMGN) Beats Q2 Earnings Estimates, to Buy Chemocentryx

by Zacks Equity Research

Amgen (AMGN) beats Q2 estimates for earnings and sales. It offers to buy ChemoCentryx (CCXI) for $3.7 billion.

Vertex (VRTX) Beats on Q2 Earnings, Ups 2022 Sales Guidance

by Zacks Equity Research

Vertex Pharmaceuticals' (VRTX) Q2 earnings and sales beat estimates. The company increases its revenue guidance for 2022.

Intellia's (NTLA) Q2 Loss Wider Than Expected, Revenues Beat

by Zacks Equity Research

Intellia Therapeutics (NTLA) posts a wider-than-expected Q2 loss while sales beat the mark. NTLA continues to advance its pipeline with developmental programs.

Amarin (AMRN) Q2 Earnings & Sales Hurt by Vazkepa Generics

by Zacks Equity Research

Amarin's (AMRN) Vazkepa sales decline year over year amid rising generic competition and COVID-related disruptions during the second quarter. The company's stock witnesses a decline on Aug 3.

BioMarin's (BMRN) Q2 Earnings Top, Voxzogo Drives Sales

by Zacks Equity Research

Biomarin Pharmaceutical's (BMRN) second-quarter earnings and sales beat estimates. BMRN slightly raises its sales guidance for the year.

Repligen (RGEN) Q2 Earnings and Sales Beat Estimates, Stock Up

by Zacks Equity Research

Repligen (RGEN) reports encouraging second-quarter results, with sales and earnings beating estimates. RGEN also raises its financial guidance for 2022

Is a Beat in Store for BioNTech (BNTX) This Earnings Season?

by Zacks Equity Research

On BioNTech's (BNTX) second-quarter earnings call, investors are expected to focus on the sales performance of its COVID-19 vaccine, Comirnaty, developed in partnership with Pfizer.

Novo Nordisk (NVO) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Novo Nordisk's (NVO) top line is likely to have been driven by sales of its Diabetes and Obesity Care products in the second quarter of 2022.

Ultragenyx's (RARE) Q2 Earnings Miss Estimates, Revenues Up

by Zacks Equity Research

Ultragenyx (RARE) reports a wider-than-expected loss in the second quarter. Nevertheless, revenues marginally beat estimates.

AstraZeneca (AZN) Beats on Q2 Earnings, Ups Sales Growth View

by Zacks Equity Research

AstraZeneca's (AZN) second-quarter results reflect a beat on both counts (revenues and earnings). AZN raises its 2022 sales growth guidance, keeping its profit forecast unchanged.

Pfizer (PFE) Q2 Earnings Top, COVID Products Drive Sales

by Zacks Equity Research

Pfizer (PFE) beats estimates for Q2 earnings and sales. It maintains the sales forecast for COVID products, Comirnaty and Paxlovid.

Is BioNTech (BNTX) a Great Value Stock Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

What's in the Cards for Sesen Bio's (SESN) Q2 Earnings?

by Zacks Equity Research

Sesen Bio's (SESN) Q2 performance is likely to reflect cost savings from the company's restructuring plans as the company continues to seek a potential partner for the further development of Vicineum.

Will AstraZeneca (AZN) Deliver a Beat This Earnings Season?

by Zacks Equity Research

Strong demand trends for AstraZeneca's (AZN) key drugs, Lynparza, Tagrisso, Imfinzi and Farxiga are likely to have driven the top line in the second quarter.